SCHEMBL4292854

SCHEMBL4292854

CCCC(=O)Nc1ccc(C(=O)Nc2ncc(Cl)s2)cc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.63
CYP2C19 P33261 2/20 0.63
CYP2C9 P11712 1/20 0.55
RAB9A P51151 3/20 0.52
NPC1 O15118 2/20 0.52
MAPT P10636 2/20 0.51
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
ALOX15 P16050 1/20 0.49
TP53 P04637 1/20 0.48
THRB P10828 2/20 0.47
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295245 0.84 ADORA2A (0.53) ADORA2ACYP2C19CYP2C9RAB9ANPC1
SCHEMBL4290822 0.84 ADORA2A (0.64) ADORA2ACYP2C19RAB9ANPC1MAPT
SCHEMBL5837008 0.84 SMN1; SMN2 (0.56) RAB9ANPC1SMN1; SMN2ALOX15
SCHEMBL4290243 0.81 IDO1 (0.48) ADORA2ARAB9ANPC1MEN1KMT2A
SCHEMBL4292546 0.81 KDR (0.59) ADORA2ARAB9ANPC1MEN1KMT2A
SCHEMBL4293906 0.78 ADORA2A (1.00) ADORA2ACYP2C19CYP2C9RAB9ANPC1
SCHEMBL4297883 0.76 ALOX15 (0.58) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL675234 0.72 TP53 (0.66) ADORA2ACYP2C19RAB9ANPC1MAPT
SCHEMBL4293155 0.72 STAT3 (0.64) CYP2C19RAB9ANPC1MAPTMEN1
SCHEMBL4293452 0.71 SMN1; SMN2 (0.59) ADORA2ARAB9ANPC1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP claimed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP claimed
CN-1870996-A N-thiazol-2-yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2006-11-29 CN claimed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US claimed
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
CN-1870996-A N-thiazol-2-yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2006-11-29 CN disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885CYP2C19 1411/4885CYP2C9 2106/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885CYP2C19 1411/4885CYP2C9 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.